,i  #aai? ,,congress  #b;d ,session  ,h4
 ,r4 #haib  ,,9 ,,! ,,h\se ,,(          
,,repres5tatives  ,april #b1 #bjbf,mr4  
,taylor introduc$ ! foll[+ bill2 :i* 0  
ref]r$ to ! ,committee on ,en]gy &      
,comm]ce  ,a ,,bill  ,to direct !       
,secret>y ( ,heal? & ,human ,s]vices to 
issue guidel9es = ! purpose ( address+ !
 problem ( nitaz5e ov]doses1 & = o!r    
purposes4  #a4 ,%ort title ,?is ,act may
 be cit$ z ! ,nitaz5e ,response ,act4   
#b4 ,assi/ance 9 respond+ to nitaz5e    
ov]doses  7a7 ,guidel9es  7#a7 ,9 g5]al 
,! ,secret>y ( ,heal? & ,human ,s]vices 
79 ?is section ref]r$ to z ! ,secret>y7 
%all issue updat$1 evid5ce-bas$ cl9ical 
guidel9es 79 ?is section ref]r$ to z !  
guidel9es7 = respond+ to nitaz5e        
ov]doses4  7#b7 ,cont5ts ,! guidel9es   
%all conta9-- 7,a7 a description ( be/  
practices = respond+ to pot5tial nitaz5e
 ov]doses1 includ+ protocols = adm9i/]+ 
naloxone2  7,b7 guidance = em]g5cy      
dep>tm5ts & hospitals 9 respond+ to     
nitaz5e ov]doses2  7,c7 guidance = rural

 & volunte] em]g5cy m$ical s]vices      
sy/ems 9 respond+ to nitaz5e ov]doses2 &
  7,d7 su* o!r in=mation z ! ,secret>y  
det]m9es appropriate4  7#c7 ,publication
 ,n lat] ?an #ahj days aft] ! date (    
enactm5t ( ?is ,act1 ! ,secret>y %all   
publi% ! guidel9es on ! public int]net  
website ( ! ,dep>tm5t ( ,heal? & ,human 
,s]vices4  7b7 ,report to ,congress ,n  
lat] ?an "o ye> aft] ! date ( enactm5t (
 ?is ,act1 ! ,secret>y %all submit to   
,congress a report conta9+ ! guidel9es &
 a description ( h[ ! guidel9es w assi/ 
9 address+ ! problem ( nitaz5e ov]doses4
  7c7 ,def9itions ,9 ?is section3  7#a7 
,nitaz5e  7,a7 ,9 g5]al ,! t]m nitaz5e  
means b5zimidazole-opioids1 includ+ any 
sub/ance 7includ+ its salts1 isom]s1 &  
salts ( isom]s7 t has a *emical /ructure
 t is sub/antially simil> to t (        
etonitaz5e or isotonitaz5e1 includ+--   
7i7 a b5zimidazole core sub/itut$ at !  
#b-position ) a b5zyl or sub/itut$ b5zyl
 gr\p2  7ii7 a basic nitrog5-conta9+    
side *a9 at ! #a-position2 &  7iii7     

exhibits agoni/ activity at ! mu-opioid 
receptor4  7,b7 ,includ$ sub/ances ,!   
t]m nitaz5e includes1 at a m9imum1 !    
foll[+3 etonitaz5e1 clonitaz5e1         
metonitaz5e1 isotonitaz5e1 protonitaz5e1
 butonitaz5e1 etodesnitaz5e1 flunitaz5e1
 ,n-pyrrolid9o etonitaz5e1 ,n-dese?yl   
isotonitaz5e1 & ,n-pip]id9yl etonitaz5e4
  7#b7 ,nitaz5e ov]dose ,! t]m nitaz5e  
ov]dose means an ov]dose involv+ nitaz5e
 or any o!r ultra-pot5t syn!tic opioid4